Journal of Hematology · 2022 · 18 citations · 13 references
MedicineHematologyOncologyCancer ImmunologyImmunotherapyMedical OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsImmune-related Adverse EventsCutaneous Squamous Cell Carcinoma ImmunotherapyDermatologic Adverse EventsEarly DiagnosisEarly Toxicity RecognitionImmune Checkpoint Inhibitor TherapyImmune-related Skin ToxicityPembrolizumab TherapyProgrammed Cell Death Protein 1 (Pd-1) Pathway
Programmed cell death protein 1 (PD-1) checkpoint inhibitors such as pembrolizumab are novel therapeutics used to treat various advanced malignancies and have been shown to increase patient survival in several studies. However, these drugs have a toxicity profile that ranges from mild side effects such as dermatitis to life-threatening complications. We present a case of pembrolizumab-induced hemophagocytic lymphohistiocytosis (HLH) in an 80-year-old patient with squamous cell carcinoma (SCC) of presumed cutaneous primary. This patient initially presented with weakness and pancytopenia, thought to be immune-related. She developed progressive anemia, after which further workup revealed concern for HLH. She recovered after a course of steroids, tocilizumab, and etoposide. To our knowledge, this patient's course is among a few rare cases of immune checkpoint inhibitor (ICI)-mediated HLH. This case highlights the need for early diagnosis and recognition of HLH as a potential toxicity related to ICI therapy.
13
Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis
Sameer A. Parikh, Prashant Kapoor, Louis Letendre et al. · Mayo Clinic Proceedings · 2014 · 322 citations
Medicine, Hematology, Pathology +13
Marc Arca, L. Fardet, Lionel Galicier et al. · British Journal of Haematology · 2014 · 217 citations · Full text